Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)

NCT07005128 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT07005128
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07005128 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open Label, Multicenter, Randomized Study of First Line Tarlatamab in Combination With Durvalumab, Carboplatin and Etoposide Versus Durvalumab, Carboplatin and Etoposide in Untreated Extensive Stage Small-Cell Lung Cancer (DeLLphi-312)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 18, 2025
Completion date
August 15, 2029
Enrollment
350 (actual)
Sites
164

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small-cell lung cancer, small-cell lung cancer